[A21-82] Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V

Last updated 15.09.2021

Project no.:
A21-82

Commission:
Commission awarded on 15.06.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy

Result of dossier assessment:

Indication of considerable added benefit

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

15.09.2021

Venetoclax in acute myeloid leukaemia: indication of considerable added benefit

Third new therapeutic indication / The median life expectancy of the patients is just over one year – and thus longer than under the appropriate comp...

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.